RATIONALE AND OBJECTIVES: Spiral computed tomography (SCT) is being evaluated as a screening tool for lung cancer. Our objective was to describe the effect of participation in SCT screening on participants' risk perceptions, worry, and expectations regarding the accuracy of the screening result. MATERIALS AND METHODS: We surveyed 60 individuals with lung cancer family history who were participating in an SCT study for the primary purpose of improving genetic linkage analysis at baseline, and then 1 and 6 months post-SCT. RESULTS: Of the 60 participants, 40 received normal results, 19 received non-negative results requiring follow-up, and 1 was diagnosed with lung cancer. At baseline, participants reported high levels of perceived lung cancer risk (64%), were concerned about developing lung cancer (94%), and the majority (84%) were not OK with receiving a non-negative SCT result when they really didn't have cancer. At 1 month post-SCT, those with a non-negative screen (n = 19) had lowered their expectations of test accuracy regarding non-negative results (54%) and reported increased levels in worry/concern (100%) and perceived risk (75%), but these effects diminished over time and returned almost to baseline levels at 6 months. CONCLUSIONS: Persons at very high empiric risk for lung cancer expect their SCT screening test to be accurate and present with high levels of lung cancer risk perception and worry/concern overall. Our findings suggest a need for risk counseling and discussion on the limitations of screening tests to accurately detect lung cancer. 2010 AUR. All rights reserved.
RATIONALE AND OBJECTIVES: Spiral computed tomography (SCT) is being evaluated as a screening tool for lung cancer. Our objective was to describe the effect of participation in SCT screening on participants' risk perceptions, worry, and expectations regarding the accuracy of the screening result. MATERIALS AND METHODS: We surveyed 60 individuals with lung cancer family history who were participating in an SCT study for the primary purpose of improving genetic linkage analysis at baseline, and then 1 and 6 months post-SCT. RESULTS: Of the 60 participants, 40 received normal results, 19 received non-negative results requiring follow-up, and 1 was diagnosed with lung cancer. At baseline, participants reported high levels of perceived lung cancer risk (64%), were concerned about developing lung cancer (94%), and the majority (84%) were not OK with receiving a non-negative SCT result when they really didn't have cancer. At 1 month post-SCT, those with a non-negative screen (n = 19) had lowered their expectations of test accuracy regarding non-negative results (54%) and reported increased levels in worry/concern (100%) and perceived risk (75%), but these effects diminished over time and returned almost to baseline levels at 6 months. CONCLUSIONS:Persons at very high empiric risk for lung cancer expect their SCT screening test to be accurate and present with high levels of lung cancer risk perception and worry/concern overall. Our findings suggest a need for risk counseling and discussion on the limitations of screening tests to accurately detect lung cancer. 2010 AUR. All rights reserved.
Authors: Pamela M McMahon; Chung Yin Kong; Bruce E Johnson; Milton C Weinstein; Jane C Weeks; Karen M Kuntz; Jo-Anne O Shepard; Stephen J Swensen; G Scott Gazelle Journal: Radiology Date: 2008-05-05 Impact factor: 11.105
Authors: Paul K J Han; Sarah C Kobrin; William M P Klein; William W Davis; Michael Stefanek; Steven H Taplin Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-03 Impact factor: 4.254
Authors: John K Gohagan; Pamela M Marcus; Richard M Fagerstrom; Paul F Pinsky; Barnett S Kramer; Philip C Prorok; Susan Ascher; William Bailey; Brenda Brewer; Timothy Church; Deborah Engelhard; Melissa Ford; Mona Fouad; Matthew Freedman; Edward Gelmann; David Gierada; William Hocking; Subbarao Inampudi; Brian Irons; Christine Cole Johnson; Arthur Jones; Gena Kucera; Paul Kvale; Karen Lappe; William Manor; Alisha Moore; Hrudaya Nath; Sarah Neff; Martin Oken; Michael Plunkett; Helen Price; Douglas Reding; Thomas Riley; Martin Schwartz; David Spizarny; Roberta Yoffie; Carl Zylak Journal: Lung Cancer Date: 2005-01 Impact factor: 5.705
Authors: Elyse R Park; Joanna M Streck; Ilana F Gareen; Jamie S Ostroff; Kelly A Hyland; Nancy A Rigotti; Hannah Pajolek; Mark Nichter Journal: Nicotine Tob Res Date: 2013-09-02 Impact factor: 4.244
Authors: Elyse R Park; Ilana F Gareen; Sandra Japuntich; Inga Lennes; Kelly Hyland; Sarah DeMello; JoRean D Sicks; Nancy A Rigotti Journal: JAMA Intern Med Date: 2015-09 Impact factor: 21.873
Authors: Elyse R Park; Ilana F Gareen; Amanda Jain; Jamie S Ostroff; Fenghai Duan; Jorean D Sicks; William Rakowski; Michael Diefenbach; Nancy A Rigotti Journal: Cancer Date: 2012-12-20 Impact factor: 6.860
Authors: Carmen Radecki Breitkopf; Pamela S Sinicrope; Kari G Rabe; Tabetha A Brockman; Christi A Patten; Robert R McWilliams; Shawna Ehlers; Gloria M Petersen Journal: Hered Cancer Clin Pract Date: 2012-06-27 Impact factor: 2.857